# Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

> **NCT07625306** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 240 (estimated)

## Conditions studied

- Acute Coronary Syndrome (ACS)

## Interventions

- **DRUG:** Pelacarsen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07625306
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-12-07
- **Final completion:** 2028-12-07
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625306, "Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*